BenevolentAI
ben excellent skin penetration experimental evidence supports high exposure in human skin at free and low exposure in blood with proposed clinical ointment strength ben ointment bid exceeds the exposure needed for inhibition in both epidermis upper dermis and lower dermis even at human in in in in free plasma levels below enabling tox package rat and pig topical safety margins fold for and fold for to dose limited a | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
March 2023
Slide
30 of 38
Related slides by other companies
DICE Therapeutics
Investor Presentation
March 2023
matches inhibition of human in | DICE Therapeutics
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Investor Conference
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io